Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.46 |
| ▸ | HTR2A | P28223 | 6/20 | 0.46 |
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 4/20 | 0.46 |
| ▸ | TNKS | O95271 | 4/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.38 |
| ▸ | CDK9 | P50750 | 4/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078326 | 0.92 | PARP1 (0.48) | KCNH2HTR2AHTR2CDRD2PARP1 | |
| SCHEMBL4069147 | 0.85 | HTR3A (0.43) | KCNH2HTR2APARP1 | |
| SCHEMBL4077282 | 0.82 | HTR2C (0.44) | KCNH2HTR2AHTR2CPARP1 | |
| SCHEMBL4074502 | 0.80 | TNKS (0.47) | HTR2APARP1TNKSTNKS2 | |
| SCHEMBL4069841 | 0.79 | HTR2C (0.42) | KCNH2HTR2AHTR2CPARP1TNKS | |
| SCHEMBL4079404 | 0.78 | PARP1 (0.43) | KCNH2HTR2AHTR2CDRD2PARP1 | |
| SCHEMBL4079214 | 0.77 | PARP1 (0.40) | KCNH2HTR2AHTR2CDRD2PARP1 | |
| SCHEMBL4068281 | 0.77 | CCR3 (0.49) | DRD2PARP1SLC6A4 | |
| SCHEMBL4078132 | 0.76 | PARP1 (0.44) | KCNH2HTR2AHTR2CPARP1TNKS | |
| SCHEMBL4075963 | 0.76 | CCR3 (0.46) | HTR2CDRD2PARP1SLC6A4MPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | claimed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | claimed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | KCNH2 2879/4885HTR2A 2360/4885HTR2C 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.